Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Accured Expenses (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Change in Accured Expenses data on record, last reported at -$2.1 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 146.14% year-over-year to -$2.1 million; the TTM value through Sep 2025 reached -$2.7 million, down 431.3%, while the annual FY2024 figure was $696000.0, 86.86% down from the prior year.
  • Change in Accured Expenses reached -$2.1 million in Q3 2025 per PLX's latest filing, down from -$610000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.3 million in Q2 2023 and bottomed at -$3.9 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is -$24263.2, with a median of $177000.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: surged 503.01% in 2023, then tumbled 590.96% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.3 million in 2021, then crashed by 127.83% to -$366000.0 in 2022, then soared by 503.01% to $1.5 million in 2023, then fell by 7.39% to $1.4 million in 2024, then plummeted by 256.59% to -$2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$2.1 million in Q3 2025, -$610000.0 in Q2 2025, and -$1.3 million in Q1 2025.